Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events

Exclusion Criteria

• •Contraindications or precautious for treatment with Wegovy© or Mounjaro© \[i.e., personal or family history of medullary thyroid cancer (MTC), personal history of multiple endocrine neoplasia type 2 (MEN2) syndrome, attempting conception, current pregnancy or breastfeeding\]
• •previous bariatric surgery or endo-bariatric procedure
• •presence of chronic pancreatitis
• •treatment with AOM within a month before enrollment
• •patients with type 1 diabetes mellitus
• •patients who underwent other major GI surgery prior to medication treatment
• •patient with underlying GI disease \[e.g., gastroparesis, celiac, Inflammatory Bowel Disease (IBD)\]
• •a positive diagnosis of small-intestinal bacterial overgrowth (SIBO)
• •patients with active gastritis, gastroenteritis
• •chronic usage of promotility drugs or laxatives
• •patients with uncontrolled mental illness
• •significant cognitive deterioration
• •alcohol consumption exceeding 1 drink per day for women and 2 drinks per day for men .
• •In addition, participants who decide not to initiate or stop Wegovy© or Mounjaro© treatment for more than two consecutive injections for any reason or who undergo bariatric surgery or endoscopic sleeve gastroplasty during the study period will be excluded from the study